PMID- 30285007
OWN - NLM
STAT- MEDLINE
DCOM- 20190111
LR  - 20190111
IS  - 2312-8852 (Electronic)
IS  - 1812-9269 (Linking)
VI  - 40
IP  - 3
DP  - 2018 Oct
TI  - Paraneoplastic syndrome in lung cancer.
PG  - 239-242
AB  - AIM: To study the nature of different variants of paraneoplastic syndrome (PNPS) 
      in lung cancer, taking into account the features of the tumorous process and the 
      complications of radiochemotherapy. PATIENTS AND METHODS: We performed an 
      analysis of the data of 1,669 patients with lung cancer aged between 24 and 
      87 years, among whom there were 89% of men and 11% of women. The ratio of small 
      cell and non-small-cell histological variants of the lung cancer was 1: 4, IB, 
      IIA, IIB, IIIA, IIIB and IV stages of cancer - 1:2:6:58:43:57. RESULTS: PNPS 
      developed in 16% of the lung cancer patients, in these patients we have detected 
      a marked increase in the disease incidence in women, the peripheral form of the 
      tumor, the apical variant of Pancoast - Tobias and adenocarcinoma, but no cases 
      of the median lower localization of the tumor. The number of the upper lobar 
      pathology was decreased, while the severity of the cancer was significantly 
      greater, which more often occurred with exudative pleurisy, germination of the 
      tumor into the chest wall and compression of the upper vena cava. The 
      21 components of PNPS pathology were established. We distributed them 
      conditionally into the musculoskeletal system lesions, variants of skin 
      vasculitis and autoimmune processes, the nature of which depended on the 
      localization and course of the tumorous process, its histological variation and 
      severity of the course. Moreover, PNPS negatively affected the development of 
      radiochemotherapy complications and worsened survival rate. CONCLUSIONS: The 
      course of PNPS in lung cancer is highly diverse, being a risk factor for a severe 
      tumorous process that worsens the survival of patients.
FAU - Dumansky, Yu V
AU  - Dumansky YV
AD  - Donetsk National Medical University, Lyman 8440, Ukraine.
FAU - Syniachenko, O V
AU  - Syniachenko OV
AD  - Donetsk National Medical University, Lyman 8440, Ukraine.
FAU - Stepko, P A
AU  - Stepko PA
AD  - Donetsk National Medical University, Lyman 8440, Ukraine.
FAU - Yehudina, Ye D
AU  - Yehudina YD
AD  - State Institution "Dnipropetrovsk State Medical Academy of the Ministry of Health 
      of Ukraine", Dnipro 49044, Ukraine.
FAU - Stoliarova, O Yu
AU  - Stoliarova OY
AD  - National Cancer Institute, Kyiv 03022, Ukraine.
LA  - eng
PT  - Journal Article
PL  - Ukraine
TA  - Exp Oncol
JT  - Experimental oncology
JID - 101230541
SB  - IM
MH  - Adenocarcinoma of Lung/*drug therapy/pathology/*radiotherapy
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Chemoradiotherapy
MH  - Combined Modality Therapy
MH  - Female
MH  - Humans
MH  - Lung/pathology
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Paraneoplastic Syndromes/*drug therapy/pathology/*radiotherapy
MH  - Survival Rate
EDAT- 2018/10/05 06:00
MHDA- 2019/01/12 06:00
CRDT- 2018/10/05 06:00
PHST- 2018/10/05 06:00 [entrez]
PHST- 2018/10/05 06:00 [pubmed]
PHST- 2019/01/12 06:00 [medline]
AID - 11607 [pii]
PST - ppublish
SO  - Exp Oncol. 2018 Oct;40(3):239-242.